CaTe Inc. Completes First Patient In for Clinical Trial of Cardiac Disease Management Program Medical Device
NQ Score
8/100
N1 Content Completeness
0.9
AI Summary (NQ-processed)
CaTe Inc. announced that it has completed the First Patient In (FPI) for the domestic clinical verification trial of its cardiac disease management program "CRS-1," aiming to validate efficacy and safety and pursue regulatory approval and commercialization.
AI Analysis
Frequently Asked Questions
- Q: How does CRS-1 support home-based rehab?
- A: CRS-1, as a SaMD, provides exercise guidance and progress monitoring at home to help patients continue cardiac rehabilitation.
- Q: What will the trial evaluate?
- A: The trial will assess efficacy and safety by comparing comprehensive home-based cardiac rehab using CRS-1 with standard outpatient rehabilitation.
- Q: When will patients be able to use it?
- A: Availability depends on clinical results and regulatory approval; commercial launch is planned after approval.